

Summary of the Preliminary Results of PEX – Listed Companies

| Main Information: | |
|---|--------------------------------|
| Name of the company: | Birzeit Pharmaceutical Company |
| Sector: | Industry |
| Trading symbol: | BPC |
| ISIN Number: | PS2008111739 |
| Date of Registration: | 1973 |
| Type of Market (First/ Second): | first |
| Authorized Capital: | 40,000,000 |
| Subscribed Capital: | 38,764,898 |
| Paid-in Capital: | 38,764,898 |
| Name of the Chairman of the Board: | Talal Nasereddin |
| Name of the Chief Executive Officer/ General Manager: | Firas Nasereddin |
| Name of the Internal Auditor: | Shorouq Abdulhameed |
| Name of the External Auditor: | HLP PS |
| Location (Head Office): | Baytonia Industrial Zone |
| Telephone Number: | 02-2967204 |
| E-mail: | INFO@BPC.COM |

| Information about the Annual Report & General Assembly Meeting: | |
|--|---------------------------------|
| Approximate date for the publication of the Annual Report: | 30/03/2026 |
| The site where the Annual Report shall be displayed for viewing by the public: | THE PEX SITE&COMPNY& NEWS PAPER |
| The proposed date for the annual Ordinary General Assembly Meeting: | THE END OF APRIL |

**Birzeit Pharmaceutical Company and its Subsidiaries
Public Shareholding Company**

**Consolidated Statement of Financial Position
As of December 31, 2025**

| | 2025 USD | 2024 USD |
|--|---------------------|---------------------|
| Assets | | |
| Current Assets | | |
| Cash and Cash Equivalent | 1,025,277 | 3,072,292 |
| Accounts Receivable, Net | 51,396,386 | 41,854,896 |
| Inventory | 12,763,777 | 11,835,012 |
| Financial Investments through Profit or Loss | 3,253,551 | 11,929,857 |
| Financial Assets at Amortized Costs | 500,000 | 500,000 |
| Other Debit Balances | 962,359 | 865,386 |
| Total Current Assets | 69,901,350 | 70,057,443 |
| Non Current Assets | | |
| Checks Under Collection - Long Term Portion | 1,255,797 | 649,531 |
| Deferred Tax Assets | 1,715,537 | 1,205,133 |
| Financial Investments through Other Comprehensive Income | 35,242,328 | 25,905,818 |
| Investment In Affiliate | 1,395,000 | 1,240,000 |
| Investment Property | 271,652 | 271,652 |
| Property, Plant and Equipment, Net | 30,424,333 | 29,491,571 |
| Total Non Current Assets | 70,304,647 | 58,763,705 |
| Total Assets | 140,205,997 | 128,821,148 |
| Owners' Equity and Liabilities | | |
| Current Liabilities | | |
| Payables and Other Credit Balances | 12,281,260 | 12,845,302 |
| Income Tax Provision | 562,308 | - |
| Total Current Liabilities | 12,843,568 | 12,845,302 |
| Non Current Liabilities | | |
| Reserve for Employees' End of Service | 12,001,141 | 11,092,856 |
| Total Liabilities | 24,844,709 | 23,938,158 |
| Owners' Equity | | |
| Share Capital | 38,764,898 | 38,764,898 |
| Treasury Stocks | (233,073) | (227,836) |
| | 38,531,825 | 38,537,062 |
| Statuary Reserve | 9,354,295 | 8,159,509 |
| Optional Reserve | 7,772,993 | 7,772,993 |
| Special Reserve | 30,000,000 | 30,000,000 |
| Retained Earnings | 26,643,077 | 17,828,253 |
| Cumulative Change in Fair Value | 1,719,688 | 1,796,094 |
| Financial Statements Currency Translation Variance | 604,860 | 107,793 |
| Equity Attributable to Owners of the Parent Company | 114,626,738 | 104,201,704 |
| Non Controlling Interests | 734,550 | 681,286 |
| Total Equity | 115,361,288 | 104,882,990 |
| Total Equity and Liability | 140,205,997 | 128,821,148 |



Mr. Talal Nassereddin
Chairman



Mr. Firas Nassereddin
Board Member and CEO

**Birzeit Pharmaceutical Company and Its Subsidiaries
Public Shareholding Company**

**Consolidated Statement of Profit or Loss
For the Year Ended December 31, 2025**

| | 2025 | 2024 |
|---|---------------------|---------------------|
| | USD | USD |
| Sales | 47,959,756 | 40,650,829 |
| Cost of Goods Sold | <u>(30,510,153)</u> | <u>(27,459,785)</u> |
| Gross Profit | 17,449,603 | 13,191,044 |
| Selling Expenses | (2,070,898) | (2,091,226) |
| Marketing Expenses | (1,280,320) | (1,146,748) |
| General and Administrative Expenses | (3,164,512) | (2,311,232) |
| Financing Expenses | (47,707) | (28,950) |
| Expected Credit Losses Provision | <u>(214,126)</u> | <u>-</u> |
| Gross Profit from Operating Activities | 10,672,040 | 7,612,888 |
| Gain (Loss) from Sale and Revaluation of Financial Assets | 496,984 | (1,428,841) |
| Gain (Loss) on Difference of Currency | 1,868,820 | (272,025) |
| Other Income | <u>46,683</u> | <u>143,260</u> |
| Net Profit Before Taxes | 13,084,527 | 6,055,282 |
| Income Tax for the year | (1,683,023) | (804,530) |
| Prior Years Taxes | (705) | (818) |
| Deferred (Amortized) Taxes | <u>510,404</u> | <u>(63,377)</u> |
| Net Profit After Taxes | 11,911,203 | 5,186,557 |
| Attributable to: | | |
| Owners of the Parent Company | 11,947,855 | 5,182,515 |
| Non Controlling Interests | <u>(36,652)</u> | <u>4,042</u> |
| | 11,911,203 | 5,186,557 |
| Earnings Per Share for Parent Company | 0.31 | 0.13 |

Mr. Talal Nassereddin
Chairman

Mr. Firas Nassereddin
Board Member and CEO

**Birzeit Pharmaceutical Company and Its Subsidiaries
Public Shareholding Company**

**Consolidated Statement of Other Comprehensive Income
For the Year Ended December 31, 2025**

| | 2025 USD | 2024 USD |
|---|---------------------|---------------------|
| Net Profit for the Year | <u>11,911,203</u> | <u>5,186,557</u> |
| Other Comprehensive Income | | |
| Items that will not be Re-classified Subsequently to Profit or Loss | | |
| Change in Fair Value for Financial Assets | <u>(76,406)</u> | <u>(3,315,630)</u> |
| | (76,406) | (3,315,630) |
| Items that may be Re-classified Subsequently to Profit or Loss | | |
| Financial Statements Currency Translation Variance | 586,983 | (42,954) |
| Fair value (losses) on Cash Hedging Contracts during the Year | - | <u>(32,547)</u> |
| | <u>586,983</u> | <u>(75,501)</u> |
| Other Comprehensive Income for the year | <u>510,577</u> | <u>(3,391,131)</u> |
| Total Other Comprehensive Income for the year | <u>12,421,780</u> | <u>1,795,426</u> |
| Attributable to: | | |
| Owners of the Company | 12,368,516 | 1,814,513 |
| Non Controlling Interests | <u>53,264</u> | <u>(19,087)</u> |
| | <u>12,421,780</u> | <u>1,795,426</u> |



**Birzeit Pharmaceutical Company and its Subsidiaries
Public Shareholding Company**

**Consolidated Statement of Changes in Equity
For the Year Ended December 31, 2025**

| | Share Capital USD | Statutory Reserve USD | Optional Reserve USD | Special Reserve USD | Retained Earnings USD | Cash Flow Hedge Reserve USD | Cumulative Change in Fair Value USD | Financial Statements Currency Translation Variance USD | Treasury Shares USD | Equity Attributable to Owners of the Company USD | Equity Attributable to the non controlling Interest USD | Total Equity USD |
|---|----------------------|-----------------------------|----------------------------|---------------------------|-----------------------------|--------------------------------------|--|---|---------------------------|--|--|---------------------|
| | | | | | | | | | | | | |
| Balance as of January 1, 2025 | 38,764,898 | 8,159,509 | 7,772,993 | 30,000,000 | 17,828,253 | - | 1,796,094 | 107,793 | (227,836) | 104,201,704 | 681,286 | 104,882,990 |
| Net Profit for the year | - | - | - | - | 11,947,855 | - | (76,405) | 497,067 | - | 11,947,855 | (36,652) | 11,911,203 |
| Other Comprehensive Income | - | - | - | - | - | - | (76,405) | - | - | 420,661 | 89,916 | 510,577 |
| Total Other Comprehensive Income for the year | - | - | - | - | 11,947,855 | - | (76,405) | 497,067 | - | 12,369,516 | 53,264 | 12,421,780 |
| Dividends paid | - | - | - | - | (1,938,245) | - | - | - | - | (1,938,245) | - | (1,938,245) |
| Transferred to Reserves | - | 1,194,786 | - | - | (1,194,786) | - | - | - | (5,237) | - | - | (5,237) |
| Change in Treasury Shares | - | - | - | - | - | - | - | - | (233,073) | - | - | (233,073) |
| Balance as of December 31, 2025 | 38,764,898 | 9,354,295 | 7,772,993 | 30,000,000 | 26,643,077 | - | 1,719,688 | 604,860 | (233,073) | 114,626,738 | 734,550 | 115,361,288 |
| Balance as of January 1, 2024 | 38,764,898 | 7,547,939 | 7,161,423 | 30,000,000 | 15,807,123 | 32,547 | 5,111,724 | 127,618 | (228,883) | 104,324,389 | 700,373 | 105,024,762 |
| Net Profit for the year | - | - | - | - | 5,182,515 | - | (3,315,630) | (19,825) | - | 5,182,515 | 4,042 | 5,186,557 |
| Other Comprehensive Income | - | - | - | - | - | (32,547) | (3,315,630) | (19,825) | - | (3,368,002) | (23,129) | (3,391,131) |
| Total Other Comprehensive Income for the year | - | - | - | - | 5,182,515 | (32,547) | (3,315,630) | (19,825) | - | (1,814,513) | (19,087) | (1,833,600) |
| Dividends paid | - | - | - | - | (1,938,245) | - | - | - | - | (1,938,245) | - | (1,938,245) |
| Transferred to Reserves | - | 611,570 | - | - | (1,223,140) | - | - | - | 1,047 | - | - | 1,047 |
| Change in Treasury Shares | - | - | - | - | - | - | - | - | (227,836) | - | - | (227,836) |
| Balance as of December 31, 2024 | 38,764,898 | 8,159,509 | 7,772,993 | 30,000,000 | 17,828,253 | - | 1,796,094 | 107,793 | (227,836) | 104,201,704 | 681,286 | 104,882,990 |



**Birzeit Pharmaceutical Company and Its Subsidiaries
Public Shareholding Company**

**Consolidated Statement of Cash Flows
For the Year Ended December 31, 2025**

| | 2025 | 2024 |
|---|--------------------|--------------------|
| | USD | USD |
| Operating Activities | | |
| Net Profit Before Tax for The Year | 13,084,527 | 6,055,282 |
| Adjustments: | | |
| Depreciation | 1,408,866 | 1,416,609 |
| Expected Credit losses | 214,126 | - |
| (Gain) Loss on Sale and Valuation of Financial Assets | (42,892) | 1,633,492 |
| (Gain) Loss on Sales of Property, Plant, and Equipment | (339) | 1,813 |
| Foreign Currency Variance | (189,379) | 10,798 |
| Provision for End of Service Indemnity | 1,046,007 | 668,421 |
| Cash Flow Before Changes in Operating Assets and Liabilities | 15,520,916 | 9,786,415 |
| (Increase) in Accounts Receivables | (9,755,616) | (5,197,245) |
| (Increase) in Checks Under Collection - Long Term Portion | (606,266) | (586,926) |
| (Increase) Decrease in Inventory | (928,765) | 1,299,941 |
| (Increase) in Other Debit Balances | (1,205,696) | (1,462,712) |
| (Decrease) Increase in Other Credit Balances | (564,042) | 4,666,815 |
| Cash Flow From Operating Activities Before Taxes and Staff Benefits | 2,460,531 | 8,506,288 |
| Income Tax Paid | (20,289) | (33,804) |
| Employee's End of Service Benefits Paid | (105,115) | (1,513,794) |
| Net Cash Flow Generated From Operating Activities | 2,335,127 | 6,958,690 |
| Investing Activities | | |
| Purchase of Financial Assets at Fair Value through Profit or Loss | (85,065) | (3,830) |
| Purchase of Financial Assets at Fair Value through Other Comprehensive Income | (1,918,672) | (3,250,000) |
| Proceeds from Sales of Financial Assets | 1,447,735 | - |
| Investment In Affiliate Company | (155,000) | (240,000) |
| Change in Non-Controlling Interest | 89,916 | (23,129) |
| Proceeds from Sales of Property, Plant and Equipment | 16,557 | - |
| Purchase of Property, Plant and Equipment | (2,331,198) | (1,524,179) |
| Net Cash Flow (Used In) Investing Activities | (2,935,727) | (5,041,138) |
| Financing Activities | | |
| Change in Treasury Shares | (5,237) | 1,047 |
| Dividends Paid | (1,938,245) | (1,938,245) |
| Net Cash Flow (Used in) Financing Activities | (1,943,482) | (1,937,198) |
| Net (Decrease) in Cash and Cash Equivalent | (2,544,082) | (19,646) |
| Financial Statements Currency Translation Variance | 497,067 | (19,825) |
| Cash and Cash Equivalent at the Beginning of the year | 3,072,292 | 3,111,763 |
| Cash and Cash Equivalent at the End of the Year | 1,025,277 | 3,072,292 |
| Non Cash Transactions: | | |
| Clearance With The Ministry of Health of Income Tax And VAT | (790,191) | (893,712) |
| Cumulative Change in Fair Value Reserve Through Other Comprehensive Income | (76,406) | (3,315,630) |
| Change in Cash Flow Hedge Reserve | - | (32,547) |
| Transfer from Investments Property to Property, Plant and Equipment | - | 5,078,489 |
| Income Tax Receivables Transferred to Other Debit Balances | 562,308 | (318,532) |
| | (304,289) | 518,068 |

